plumbagin has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boudreau, LH; Gharib, E; Pichaud, N; Robichaud, GA; Veilleux, V | 1 |
| Fu, C; Gong, Y; Niu, M; Sang, W; Shi, X; Sun, Z; Wang, Y; Xu, K; Xu, L; Zhu, F | 1 |
2 other study(ies) available for plumbagin and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming.
Topics: Antineoplastic Agents; Cell-Derived Microparticles; Cytarabine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
Plumbagin reduces chronic lymphocytic leukemia cell survival by downregulation of Bcl-2 but upregulation of the Bax protein level.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; Cell Survival; Down-Regulation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Up-Regulation | 2016 |